These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 26481591)

  • 21. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
    JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
    Bertrand ME; Esplugas E; Piessens J; Rasch W
    Circulation; 2000 Jan; 101(2):131-6. PubMed ID: 10637198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
    Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
    Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study.
    Giustino G; Baber U; Mastoris I; Vlachojannis GJ; Yu J; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Nikolsky E; Wong SC; Theodoropoulos KN; Dangas GD; Mehran R
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):703-9. PubMed ID: 26481591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
    Reed M; Meier P; Tamhane UU; Welch KB; Moscucci M; Gurm HS
    JACC Cardiovasc Interv; 2009 Jul; 2(7):645-54. PubMed ID: 19628188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis of the risk of total cardiovascular events of isosmolar iodixanol compared with low-osmolar contrast media.
    Zhang BC; Wu Q; Wang C; Li DY; Wang ZR
    J Cardiol; 2014 Apr; 63(4):260-8. PubMed ID: 24397991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative tolerability of contrast media used for coronary interventions.
    Esplugas E; Cequier A; Gomez-Hospital JA; Del Blanco BG; Jara F
    Drug Saf; 2002; 25(15):1079-98. PubMed ID: 12452733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic impact of contrast-induced acute kidney injury associated with invasive cardiology: role of iso-osmolar contrast media in Germany, Italy, Poland, and Spain.
    De Francesco M; Ronco C; Wacinski PJ; Wessely R; Hernández F; Lamotte M
    J Med Econ; 2016; 19(2):158-68. PubMed ID: 26451530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients.
    Solomon R
    Kidney Int; 2005 Nov; 68(5):2256-63. PubMed ID: 16221227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Effect of Contrast Media Type on the Incidence of Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis.
    Eng J; Wilson RF; Subramaniam RM; Zhang A; Suarez-Cuervo C; Turban S; Choi MJ; Sherrod C; Hutfless S; Iyoha EE; Bass EB
    Ann Intern Med; 2016 Mar; 164(6):417-24. PubMed ID: 26830055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrotoxicity of contrast media following cardiac angiography: pathogenesis, clinical course, and preventive measures, including the role of low-osmolality contrast media.
    Spinler SA; Goldfarb S
    Ann Pharmacother; 1992 Jan; 26(1):56-64. PubMed ID: 1606346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephropathy after administration of iso-osmolar and low-osmolar contrast media: evidence from a network meta-analysis.
    Biondi-Zoccai G; Lotrionte M; Thomsen HS; Romagnoli E; D'Ascenzo F; Giordano A; Frati G
    Int J Cardiol; 2014 Mar; 172(2):375-80. PubMed ID: 24502883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Race and contrast-induced nephropathy in patients undergoing coronary angiography and cardiac catheterization.
    Chawla R; Turlington J; Arora P; Jovin IS
    Int J Cardiol; 2017 Mar; 230():610-613. PubMed ID: 28040287
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.